Tokyo, Japan – Sarcoidosis is a complex inflammatory disease that causes the harmful accumulation of tiny clumps of cells called granulomas in the body. In most cases, sarcoidosis manifests in the lungs and lymph nodes. However, in approximately 10% of patients, the heart is affected; this condition is known as...
Latest News
BOSTON, Mass. – About eight million people live with Type 1 diabetes (T1D) worldwide, a chronic autoimmune condition in which the body attacks and destroys its own insulin-producing β-cells (pronounced “beta”) in the pancreas, leading to a lack of insulin and inability to regulate blood sugar. It’s not known why...
Matsumoto, Japan – Early detection and treatment of hereditary transthyretin-related amyloidosis via genetic counseling are crucial. Yet, not all at-risk individuals seek genetic counseling, and management for presymptomatic carriers remains unclear. To tackle these knowledge gaps, a research team from Japan conducted a retrospective study on over 200 people who...
Matsumoto, Japan – Metabolic dysfunction–associated steatotic liver disease (MASLD) is a well-known risk factor for colorectal cancer (CRC). MASLD has emerged as a heterogenous disease tightly linked to metabolic dysfunction and has been redefined under the umbrella term ‘steatotic liver disease’ (SLD). However, CRC risk variations across different SLD subgroups remain unknown....
CLONMEL, Ireland – Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced today that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a lifesaving treatment that is often in shortage and the...
CLONMEL, Ireland – Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, announces the appointment of Chief Commercial Officer Nicholas Holsman, a highly experienced U.S. industry executive with in-depth experience in scaling oncology & specialty pharma enterprises. Shorla specializes in developing innovative oncology drugs, with a focus on orphan and pediatric cancers....
– Favorable reimbursement policies across many countries are estimated to drive the short bowel syndrome market during the forecast period – High cost of parenteral nutrition will boost the demand for SBS drugs extensively, eventually increasing the growth rate of the global market ALBANY – Transparency Market Research, New York: The growing prevalence...
Compared with standard whole-body magnetic resonance imaging (WBMRI), a short WBMRI protocol may reduce the length of MRI tests, while maintaining high sensitivity and specificity, among patients with multiple myeloma (MM) undergoing diagnostic testing, according to research published in Diagnostics. MM is the second-most common hematologic cancer, following non-Hodgkin lymphomas, and...
PRINCETON, N.J. & TOKYO & WALTHAM, Mass. — Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of...
Chengdu, China – Prof. Changyang Gong’s team (Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) wrote this review, in which Dr. Xianzhou Huang leads most of the research. Rapid growth in nanoparticles as delivery systems holds vast promise to promote therapeutic approaches...